688238 Obio Technology
- 6.26
- +0.09+1.46%
Obio Technology News
Heyuan Biotech (688238) 2023 Annual Report 2024 Quarterly Report Comment: CGTCRO is growing steadily, new orders from CDMO are picking up and improving
Event: On April 28, 2024, Heyuan Biotech released its 2024 quarterly report. The company's revenue in 2023 was 205 million yuan, down 29.69% year on year, and net profit to mother - 128 million yuan, year-on-year
Heyuan Biotech (688238): CDMO gradually recovers and expects further release of production capacity in Lingang
The 2023 results are in line with our expectations. Revenue for the first quarter of 2024 exceeded our expected 2023 results: revenue of $205 million, -29.69% year over year; net loss to mother of $128 million; net loss to mother of $128 million; net loss after deducting non-net losses1
The biomedical sector fluctuated higher, and Weixinkang went up and down in a straight line. Osecon was previously closed, and Aoxiang Pharmaceutical, Heyuan Biotech, Haichuang Pharmaceutical, and Bohui Innovation had the highest gains.
The biomedical sector fluctuated higher, and Weixinkang went up and down in a straight line. Osecon was previously closed, and Aoxiang Pharmaceutical, Heyuan Biotech, Haichuang Pharmaceutical, and Bohui Innovation had the highest gains.
OBiO Technology Will Showcase at American Society of Gene & Cell Therapy
OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene...
Express News | Heyuan Biotech: Net loss of 42.1703 million yuan in the first quarter
Heyuan Biotech (688238.SH) announced its 2023 annual results, with a net loss of 128 million yuan, changing from profit to loss over the previous year
Heyuan Biotech (688238.SH) disclosed its 2023 annual report, and the company achieved revenue of 2 in 2023...
5.2 million restricted shares of Heyuan Biotech (688238.SH) will be listed and circulated on March 22
Heyuan Biotech (688238.SH) announced that the total number of shares in circulation in the company's current stock listing is 5.2 million shares, which are listed and in circulation...
Heyuan Biotech (688238.SH): The first phase of the employee stock ownership plan will raise no more than 50 million yuan
On February 7, Gelonghui (688238.SH) announced the first phase of the employee stock ownership plan. The total amount of self-financing funds raised by employees in the employee stock ownership plan was no more than 30 million yuan, which was a ratio of 6:4 with the incentive fund withdrawn by the company. The amount of incentive funds withdrawn by the company according to the “Remuneration Management System” did not exceed RMB 20 million. The total amount of capital to be raised in this employee stock ownership plan is not more than RMB 50 million. Using “shares” as the subscription unit, each share is 1 yuan, and the total subscription share is no more than 50 million shares. The specific share is determined based on the actual amount of funding contributions.
Heyuan Biotech (688238): CDMO business is under pressure and capacity utilization is expected to increase
The company predicts a net loss of 113-129 million yuan in 2023 The company issued a performance forecast: in 2023, revenue of 2.02-224 million yuan, a year-on-year decrease of 23-31%, and a net loss of 1.13-1.2 million yuan to the mother
Heyuan Biotech (688238.SH): Expected net loss of 113 million yuan to 129 million yuan in 2023
On January 29, Gelonghui (688238.SH) announced that according to preliminary estimates by the finance department, it is expected to achieve operating income of 20.200 million yuan to 224 million yuan in 2023, a decrease of 67.3043 million yuan to 89.03 million yuan over the same period last year, a year-on-year decrease of 23% to 31%. The company expects to achieve net profit attributable to owners of the parent company in 2023 compared with the same period last year, from -129.00 million yuan to -11.30 million yuan, a decrease of 15,202.52 from the same period last year
Heyuan Biotech (688238.SH): Currently, there are more than 280 cooperative CDMO projects in China
On December 14, Heyuan Biotech (688238.SH) said on an interactive platform that, as a leading domestic company that lays out gene and cell therapy, Heyuan Biotech has accumulated rich project experience in gene and cell therapy drug development with a large number of product development experience, advanced processes and production capacity, a high standard quality system, and a high-level technical service team, and has accumulated rich project experience in gene and cell therapy drug development, providing high-quality CRO/CDMO services for new drug projects in various fields such as oncolytic viruses, adenoviruses, lentiviruses, mRNA plasmids, CART, stem cells, NK cells, etc. Currently, domestic cooperation in CDM has accumulated
Heyuan Biotech (688238.SH): Currently, the company has sufficient orders, and production and operation are orderly
On December 14, Gelonghui (688238.SH) said on an interactive platform that at present, the company has sufficient orders and orderly production and operation; the company's directors have never resigned, and the core management has remained stable. Recently, the company announced the adjustment of the number of board members based on the company's management development needs, further optimization of the governance structure, which is conducive to improving the decision-making efficiency of the board of directors and better implementation of the “Management Measures for Independent Directors of Listed Companies”, which came into effect on September 4, 2023.
The concept of gene editing weakens and metabiotics falls by more than 10%
Gelonghui, December 11 | Heyuan Biotech fell more than 10%, and Shu Taishen, Ruiang Gene, Berry Gene, and Ternary Gene quickly followed suit.
Heyuan Biotech (688238.SH) will list 223.47 million restricted shares for circulation on December 11
Heyuan Biotech (688238.SH) announced that the restricted shares listed and circulated this time are part of the company's initial public offering...
Pharmaceutical stocks fell, Heyuan Biotech fell more than 9%
Gelonghui November 22 | Heyuan Biotech fell more than 9%, and Changshan Pharmaceutical, Wisdom Pharmaceutical, Boteng Co., Ltd., Xiangxue Pharmaceutical, and Zhongsheng Pharmaceutical followed suit.
The concept of gene editing strengthened and metabiotics surged by more than 10%
Gelonghui November 21 | Heyuan Biotech surged more than 10%, Berry Gene hit a rise or fall, and Nanmo Biotech, Australian Ocean Health, Novo Zhiyuan, and BGI followed suit. According to the news, the British regulatory agency 1 has approved the application of Casgevy therapy developed based on CRISPR gene editing technology to treat two types of blood diseases. This is the first CRISPR gene editing therapy approved for application in the world. This treatment was jointly developed by Forte Pharmaceuticals of the United States and the Swiss CRISPR therapy company.
Heyuan Biotech (688238.SH): 6.9797 million restricted shares will be listed and distributed from November 27
Heyuan Biotech (688238.SH) issued an announcement on the listing and circulation of some restricted shares in the initial public offering. This time...
CRO concept stocks rose, Tiger Pharma rose more than 6%
Gelonghui November 6 | Heyuan Biotech and Tiger Pharma rose more than 6%, while Medici and Kanglong Chenghua followed suit.
[BT Financial Report Instantaneous Analysis] Heyuan Biotech's 2023 Quarterly Report: Revenue is declining, R&D investment is increasing, and development potential in the field of gene therapy needs to be tapped
This financial report was announced at 09:11:31 2023-10-26 Heyuan Biotech (stock code: 688238) is a biotechnology company focusing on the field of gene therapy. It provides basic research services for gene therapy, including CRO services such as treatment vector development and gene function research, and also provides CDMO services such as IND-CMC pharmaceutical research and clinical sample GMP production for gene drug development. Based on its rich gene therapy carrier technology, process and GMP production experience, the company provides research institutes, hospitals, pharmaceutical companies, etc. with a full range of gene and cell therapy CRO and
Heyuan Biotech (688238): Steady growth in CRO business and release of new production capacity is expected to drive CDMO business recovery
Event description The company released its 2023 three-quarter report. In the first three quarters of 2023, the company achieved operating income of 137 million yuan, a year-on-year decrease of 36.38%; realized net profit of 71.0996 million yuan, a year-on-year decrease of 309 million yuan
Analysis
Price Target
No Data
